Oncolytics Biotech (ONCY) announced that the U.S. FDA has granted Fast Track designation to pelareorep in combination with Roche’s (RHHBY) anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel, for the treatment of advanced/metastatic pancreatic ductal adenocarcinoma. This represents pelareorep’s second FDA Fast Track designation.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ONCY:
- Oncolytics to hold a key opinion leader webinar
- Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
- Oncolytics reports Q3 EPS (8c), consensus (8c)
- Oncolytics reports interim results from Phase 1/2 GOBLET study
- Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights